The HPV vaccine mandate controversy.

[1]  Christophe Fraser,et al.  Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. , 2007, Vaccine.

[2]  J. Bost,et al.  Impact of addition of philosophical exemptions on childhood immunization rates. , 2007, American journal of preventive medicine.

[3]  Erik J. Dasbach,et al.  Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.

[4]  J. Colgrove.  The ethics and politics of compulsory HPV vaccination. , 2006, The New England journal of medicine.

[5]  H. Cubie,et al.  Public awareness of human papillomavirus , 2006, Journal of medical screening.

[6]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[7]  X. Castellsagué,et al.  Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women , 2006, Pediatrics.

[8]  Lawrence H Moulton,et al.  Nonmedical exemptions to school immunization requirements: secular trends and association of state policies with pertussis incidence. , 2006, JAMA.

[9]  S. Kalichman,et al.  HIV Treatment Beliefs and Sexual Transmission Risk Behaviors among HIV Positive Men and Women , 2006, Journal of Behavioral Medicine.

[10]  G. Zimet,et al.  Chapter 24: Psychosocial aspects of vaccine acceptability. , 2006, Vaccine.

[11]  C. Wheeler,et al.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.

[12]  B. Lo.  HPV vaccine and adolescents' sexual activity , 2006, BMJ : British Medical Journal.

[13]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[14]  S. Teret,et al.  Compulsory vaccination and conscientious or philosophical exemptions: past, present, and future , 2006, The Lancet.

[15]  C. Kemper,et al.  Use of and Adherence to Antiretroviral Therapy Is Associated With Decreased Sexual Risk Behavior in HIV Clinic Patients , 2005, Journal of acquired immune deficiency syndromes.

[16]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[17]  Matthew M Davis,et al.  Associations of daycare and school entry vaccination requirements with varicella immunization rates. , 2005, Vaccine.

[18]  G. Martinez,et al.  Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002. , 2004, Vital and health statistics. Series 23, Data from the National Survey of Family Growth.

[19]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[20]  G. Sanders,et al.  Evaluating Human Papillomavirus Vaccination Programs , 2004, Emerging infectious diseases.

[21]  M. Schiff,et al.  Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. , 2004, Vaccine.

[22]  G. Marks,et al.  Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. , 2004, JAMA.

[23]  Milton C Weinstein,et al.  Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. , 2004, Journal of the National Cancer Institute.

[24]  Shalini L Kulasingam,et al.  Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. , 2003, JAMA.

[25]  H. Margolis,et al.  Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. , 2002, The Journal of infectious diseases.

[26]  D. Kirby.  The impact of schools and school programs upon adolescent sexual behavior , 2002, Journal of sex research.

[27]  D. Vlahov,et al.  Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users , 2001, AIDS.

[28]  R. Hamman,et al.  Individual and community risks of measles and pertussis associated with personal exemptions to immunization. , 2000, JAMA.

[29]  A. Hinman,et al.  The immunization system in the United States - the role of school immunization laws. , 1999, Vaccine.

[30]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[31]  A. Hinman,et al.  Childhood immunization: laws that work. , 2002, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.

[32]  L. Rodewald,et al.  Processes for obtaining nonmedical exemptions to state immunization laws. , 2001, American journal of public health.

[33]  H. Margolis,et al.  The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. , 1990, JAMA.